OSLO, Norway, Feb. 2, 2016 (GLOBE NEWSWIRE) — Targovax has submitted a study protocol to the regulatory authorities in Spain to assess its ONCOS-102 product in combination with chemotherapy in patients with malignant pleural mesothelioma (MPM), a rare type of lung cancer associated with exposure to asbestos.
“This submission marks another important step for Targovax, delivering on our strategy to initiate trials to study the ONCOS-102 platform in multiple indications” says Gunnar Gårdemyr, CEO of Targovax.
Spain is expected to become an important country in this study, therefore submission to the competent authorities in Spain is an important step in the clinical development plan.
“In this trial, we will study a patient group which is in great need of better therapies. It will also be the first time to assess ONCOS-102 in combination with chemotherapy. As a result, the study will give a better picture of the benefits of Targovax’ immune therapy alongside existing standard of care” continues Gårdemyr.
MPM is highly malignant with a 5-year survival of only 5 to 10%. Most patients are diagnosed too late for surgical intervention for whom standard of care chemotherapy will provide a median overall survival of approximately 1 year.
In a recently completed phase I study, ONCOS-102 was seen to induce TILs (tumor infiltrating lymphocytes) in 11/12 patients in a mixed population of solid tumors including MPM and detection of tumor specific T-cells in peripheral blood demonstrating systemic and profound immune activation at lesional level.
The study is a randomized phase II study with a phase Ib safety lead in cohort of 30 patients with first line MPM patients and second line patients who are eligible for treatment with pemetrexed and cisplatin, the standard of care chemotherapy in this indication. The study’s main objectives are determination of safety, immune activation at lesional level and in peripheral blood, clinical response and the correlation between clinical outcome and the immunological activation. Several investigational sites in Europe will participate in this study, which is expected to start during the first half of 2016.
ONCOS-102 has orphan drug status in Europe and the USA in MPM.
About Targovax: “Arming patients’ immune system to fight cancer”
Targovax is a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients. Targovax has a broad and diversified immune therapy portfolio and aim to become a leader in its area. The company is currently developing two complementary and highly targeted approaches in immuno-oncology:
Oncos 102 is a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes targeting solid tumors. This treatment may reinstate the immune system’s capacity to recognize and attack cancer cells.
TG01 and TG02 are part of a peptide-based immunotherapy platform targeting the difficult to treat RAS mutations found in more than 85% of pancreatic cancers, 50% of colorectal cancer and 20-30% of all cancers. Targovax works towards demonstrating that TG vaccines will prolong time to cancer progression and increase survival.
The product candidates will be developed in combination with multiple treatments in several cancer indications, including checkpoint inhibitors. Targovax also has a number of other cancer immune therapy candidates in the early stage of development. For more information go to www.targovax.com.
For further information, please contact:
Phone: +41 798 340 585
Phone: +47 906 56 525